TISSIUM secures 60 million euros to support its commercial, clinical, and platform expansion activities

▤ Summary

TISSIUM secured a total of 60 million euros to support commercial, clinical, and platform expansion work. The package combines a 30 million euro Series D2 equity round with a potential 30 million euro facility from the European Investment Bank. The company recently received FDA market authorization for COAPTIUM CONNECT and is now pushing its first product into the U.S. market. The new capital will help TISSIUM scale sales, advance clinical programs, and expand its proprietary biomorphic polymer platform.

$ Funding

▦ Linked Companies